(Q37779808)

23 August 2017

1 reference

title

Safinamide in the treatment of Parkinson's disease. (English)

1 reference

23 August 2017

1 reference

1

Anthony H V Schapira

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

13

1 reference

23 August 2017

page(s)

2261-2268

1 reference

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Non-motor symptoms of Parkinson's disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

The diagnosis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Trends in Parkinson's disease related mortality in England and Wales, 1993-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Is Parkinson's disease-related mortality declining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Factors affecting health-related quality of life amongst Asian patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Medications used to treat Parkinson's disease and the risk of gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Subthalamic deep brain stimulation and impulse control in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Excessive daytime sleepiness in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Non-dopaminergic treatments in development for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Cognitive function in early Parkinson's disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Addenbrooke's Cognitive Examination validation in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

The assessment of depression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Unraveling depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Mobility and balance in Parkinson's disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Population-based case-control study of morale in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Parkinson's disease and nursing home placement: the economic impact of the need for care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Safinamide: from molecular targets to a new anti-Parkinson drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Perspectives on recent advances in the understanding and treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Disease-modifying pathways in neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Neurobiology and treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Parkinson's disease: from monogenic forms to genetic susceptibility factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Professional exposure to pesticides and Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Elevated serum pesticide levels and risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Mitochondria in the aetiology and pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Complex I: inhibitors, inhibition and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Oxidative stress and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Future directions in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Science, medicine, and the future: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Clinical trials of neuroprotection for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Progress in neuroprotection in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Improvement of motor function in early Parkinson disease by safinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Body weight in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

NICE guideline for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Treatment options in the modern management of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Bimodal administration of entacapone in Parkinson's disease patients improves motor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Drug-induced fibrotic valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Dopamine agonists and neuroprotection in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Movement disorders: advances in cause and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511612

10.1517/14656566.2010.511612

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference